However, following RT a positive trend of Th2 cytokines is observed in patients with early progressing disease, without the expected surge of IFNγ that was instead observed in patients with better outcome.
2
—
—
The sentences
The Combi-AD trial, comparing the combination of dabrafenib and trametinib with placebo in patients with stage IIIA(> 1 mm)/B/C melanoma with a BRAF-V600E/K mutation demonstrated also a highly significant benefit with a HR of 0.47 and 12 months and 18 months RFS-rate differences of 32% and 31% respectively.